Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL BehringLEXINGTON, Mass. and AMSTERDAM, June 20, 2023 uniQure N.V. , a leading gene therapy company advancing. | June 20, 2023
uniQure Inc : uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an. | May 15, 2023
~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an
~ Clinical update from U.S. Phase I/II trial in Huntington's disease expected in second quarter 2023 ~ ~ Continued progress towards initiating two new Phase I/II clinical studies for AMT-260 in refractory